87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear –
- Data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer –
- Management will review results during a webcast today at 8:00 a.m. EDT -
Decibel management will host a webcast regarding these interim analysis results today, Tuesday, June 28, 2022 at 8:00 a.m. EDT. The live webcast may be accessed online.
A replay of the webcast will be available online in the investor relations section of the Decibel website at www.decibeltx.com and will be archived there for 90 days.
https://finance.yahoo.com/news/decibel-therapeutics-reports-positive-data-110000908.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.